Arete Wealth Advisors LLC Has $268,000 Position in Sanofi (NASDAQ:SNY)

Arete Wealth Advisors LLC reduced its holdings in Sanofi (NASDAQ:SNY) by 6.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,653 shares of the company’s stock after selling 305 shares during the period. Arete Wealth Advisors LLC’s holdings in Sanofi were worth $268,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Barrow Hanley Mewhinney & Strauss LLC raised its holdings in Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares during the period. Magnetar Financial LLC raised its holdings in Sanofi by 1,153.1% in the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after purchasing an additional 2,306,286 shares during the period. Jennison Associates LLC raised its holdings in Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after purchasing an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans raised its holdings in Sanofi by 28,890.2% in the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after purchasing an additional 1,424,289 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on SNY shares. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Trading Down 0.4 %

Shares of NASDAQ:SNY opened at $46.80 on Friday. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company’s fifty day simple moving average is $51.02 and its 200 day simple moving average is $52.04. The firm has a market cap of $118.77 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 1.24 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the business posted $2.55 earnings per share. As a group, research analysts forecast that Sanofi will post 4.27 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.